Wall Street analysts forecast that ContraFect Co. (NASDAQ:CFRX - Get Rating) will announce earnings of ($0.33) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ContraFect's earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.35). ContraFect reported earnings per share of ($0.18) during the same quarter last year, which would suggest a negative year over year growth rate of 83.3%. The firm is scheduled to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that ContraFect will report full-year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.34) to ($0.95). For the next financial year, analysts forecast that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.33) to ($1.10). Zacks' EPS averages are an average based on a survey of analysts that cover ContraFect.
ContraFect (NASDAQ:CFRX - Get Rating) last issued its quarterly earnings results on Thursday, March 24th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.13.
A number of equities research analysts have recently commented on CFRX shares. StockNews.com started coverage on ContraFect in a research note on Wednesday. They issued a "sell" rating on the stock. SVB Leerink reduced their price objective on shares of ContraFect from $14.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday, February 16th.
Several hedge funds have recently bought and sold shares of CFRX. Wedmont Private Capital bought a new position in shares of ContraFect during the fourth quarter valued at $25,000. Moody Lynn & Lieberson LLC purchased a new position in ContraFect in the 4th quarter worth about $26,000. Mayflower Financial Advisors LLC bought a new position in ContraFect during the 4th quarter valued at about $26,000. Acadian Asset Management LLC purchased a new stake in shares of ContraFect during the 4th quarter valued at about $46,000. Finally, WealthTrust Axiom LLC grew its stake in shares of ContraFect by 20.0% in the fourth quarter. WealthTrust Axiom LLC now owns 30,025 shares of the biotechnology company's stock worth $78,000 after acquiring an additional 5,000 shares during the period. Hedge funds and other institutional investors own 58.44% of the company's stock.
CFRX stock opened at $3.58 on Wednesday. The business has a 50 day moving average of $3.59 and a 200 day moving average of $3.29. The firm has a market cap of $140.81 million, a PE ratio of -6.39 and a beta of 0.57. ContraFect has a twelve month low of $2.11 and a twelve month high of $4.76.
About ContraFect (Get Rating)
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.
Further Reading
Get a free copy of the Zacks research report on ContraFect (CFRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider ContraFect, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ContraFect wasn't on the list.
While ContraFect currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
